The Times seems to have gone out of its way to publish a commentary that the paper’s own reporting shows is absolutely false on all counts. This is irresponsible media at its worst.
In the world of emergency contraception (EC), August 1, 2012 also means one EC option just got a lot more affordable for many women.
Today the Washington Post swallowed hook, line, and sinker the rhetoric of the far right anti-choice community on “ella,” a new emergency contraceptive now available to women in the United States, calling it “controversial.”
A new form of emergency contraception, ella, is now available to women in the United States. And predictably, the far right is up in arms.
It would be nice if Cannon could treat all women the way he’d like his own wife, sisters and daughters to be treated; with respect and privacy to make their own reproductive decisions.
The new post-coital contraceptive, ulipristal (also known as ella), has been FDA approved. As a doctor who wants women to have as many choices as possible, I’m thrilled to have another option to offer to women. But this particular new choice actually leaves me feeling queasy.
Yesterday we critiqued the Washington Post‘s front-page article on Virginia Attorney General Ken Cuccinelli’s efforts to justify his ideological war on women’s rights by professing a concern for their health and safety. Today, a Post editorial addresses the issue. It’s not enough.
On Friday, August 13th, 2010, the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs approved the sale and use of “ella,” the brand name for a new form of emergency contraception that will provide women with more options to prevent unplanned pregnancies. Health advocates welcomed the news.
A blatocyst is an embryo! A pregnacy test is effective at 4 days except that no test is! No wonder the anti-choice movement seems so confused.
An advisory committee of the Food and Drug Administration has found that a new emergency contraceptive is safe and effective, and labeling should not restrict access to product.